Thu, Jul 24, 2014, 12:22 PM EDT - U.S. Markets close in 3 hrs 38 mins

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • jhsudds jhsudds May 17, 2013 3:41 PM Flag

    Cedars Sinai study

    Cedars-Sinai launches new clinical trial to study effects of cabozantinib in prostate cancer patients

    The Cedars-Sinai clinical trial will involve up to 40 adult patients who will all receive cabozantinib. During the first three cycles, patients will be evaluated twice per month so that doctors can adjust dosages. Participants will undergo imaging tests every two months to track their cancers. Patients can continue treatment for as long as they are receiving a benefit.

    The FDA-approved clinical trial will allow physicians and scientists to focus on a blood- and tissue-based analysis of disease markers that will provide insight into how cabozantinib (XL184) works in patients with this specific type of cancer and other cancers as we

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • go to twigma and type in cedar Sinai or elelixis and keep it quite until I finish buying news came out 5-16-13

    • Where are you getting this information? Is it new or old?

    • "Doctors in the Samuel Oschin Comprehensive Cancer Institute are studying the impact of cabozantinib (XL184) in men with prostate cancer that is resistant to medical and surgical treatments and has spread to other parts of their bodies, including the liver or lungs. Physicians and research scientists are examining the development of the disease among men excluded from other ongoing clinical trials because of the severity of their illnesses.

      Cabozantinib inhibits various molecular signals, stemming the spread of cancer by killing tumor cells while blocking their escape pathways. It has been shown in early clinical trials to have an effect on men with the metastatic form of prostate cancer – both before and after chemotherapy – by reducing pain and improving bone scans".

      Cancer researchers believe the new clinical trial of the drug offers an opportunity to make important scientific discoveries for treating the severest forms of prostate cancer, the second leading cause of cancer death among American men and a leading cause of cancer mortality worldwide.

      "Given the results of previous clinical trials, these patients represent a population that could benefit from the therapy," said Edwin M. Posadas, MD, medical director of the Urologic Oncology Program at the Samuel Oschin Comprehensive Cancer Institute and the lead investigator of the new study".

    • Thanks jhsudds ! As always your posts are worthwhile.That can't be said for alot of other posters.

 
EXEL
4.0801+0.3001(+7.94%)12:21 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.